Ovarian cancer screening saves few lives

	Tweet

The best currently available screening tests can only slightly reduce ovarian cancer deaths. That is the conclusion of new research published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The results suggest that strategies other than screening, such as prevention and better treatments, will be needed to significantly lower the number of women who die from ovarian cancer.

No screening program for ovarian cancer has been proven to save lives, mainly because the disease is uncommon and tends to grow and spread without causing symptoms. Laura Havrilesky, MD, MHSc, of the Duke University Medical Center in Durham, led a team that recently designed a computer-based model of the progression of ovarian cancer from early to late stages. The model, which takes into account the fact that certain ovarian cancers are slow growing while others grow more quickly, can test the effectiveness of screening strategies for reducing the number of deaths from ovarian cancer.

The researchers discovered that annual screening for ovarian cancer is likely to result in only a modest reduction in mortality from the disease. “If we assume ovarian cancers grow and spread at different rates, the best screening strategy available will only reduce the number of women dying from this cancer by 11 percent.

This is partially because the slower growing cancers are more likely to be caught by a screening test,” said Dr. Havrilesky. The findings support the commonly held clinical impression that many early stage ovarian cancers are destined to remain in the early stages for some time, while advanced stage cancers have likely spread rapidly.

More sensitive screening tests will be needed to significantly reduce deaths attributed to ovarian cancer. For now, other measures that focus on prevention and treatment should be pursued to save women’s lives.

In an accompanying editorial, Patricia Hartge, MA, ScD, of the National Cancer Institute in Rockville noted that for women who are at a higher risk for developing ovarian cancer—for example because of the presence of known cancer-causing gene mutations or a significant family history of ovarian cancer—screening presents a more hopeful picture. In this regard, targeted screening could help reduce deaths attributed to ovarian cancer. She added that the results from ongoing randomized clinical trials will provide the strongest evidence about the potential for reducing ovarian cancer deaths through screening.

###

Contact: Jennifer Beal

44-124-377-0633
Wiley-Blackwell

RELATED STORIES:
Avastin helps in ovarian cancer but effects fade   Vascular marker of ovarian cancer identified   An experiment in earlier detection of ovarian cancer   Proteins show promise for ovarian cancer screening   Women often opt to surgically remove their breasts, ovaries to reduce cancer risk   Researchers find possible genetic keys to surviving epithelial ovarian cancer   Study Explains High Platelets in Ovarian Cancer Patients; Survival Reduced   Physical activity does not ward off ovarian cancer   PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer   Goodness of milk ‘offset by ovarian cancer risk’   Selumetinib Controlled Recurrent Low-Grade Serous Ovarian Cancer   Motor protein may offer promise in ovarian cancer treatment   ‘Trojan Horse’ particle sneaks chemotherapy in to kill ovarian cancer cells   Ovarian transplantation: New technique gives greatly improved results in this delicate operation   Ginger Causes Ovarian Cancer Cells to Die   Removal of Ovaries Decreases Cancer Risk for Women at High-Risk   Higher BMI Tied to Ovarian Cancer Risk   Ovarian cancer screening approach may be flawed   Short-term OC use cuts ovarian cancer risk   Project Achilles Pinpoints Vulnerabilities in Ovarian Cancer   Excess pounds may raise ovarian cancer risk   Commercial Sale of Ovarian Cancer Test Deemed Illegal by FDA

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]